Table 3.
Crude median overall survival, crude 1-year survival and adjusted hazard ratios for patients diagnosed with metastatic pancreatic cancer between 2007 and 2011 in the Netherlands (N = 5385)
| Crude median survival (weeks) | Crude 1-year survival (%) | Multivariable HR (95 % CI) | |
|---|---|---|---|
| Diagnosed in high-volume incidence centera | |||
| Yes | 9.9 | 6.7 | 0.86 (0.94–1.06) |
| No | 9.4 | 5.5 | 1.00 (reference) |
| Treated in high-volume treatment centera,b | |||
| Yes | 28.4 | 21.3 | 0.76 (0.67–0.87) |
| No | 22.9 | 11.6 | 1.00 (reference) |
| Diagnosed in high-volume surgical centera | |||
| Yes | 14.7 | 11.9 | 0.74 (0.66–0.83) |
| No | 9.3 | 5.4 | 1.00 (reference) |
aDifferent types of high-volume centers were added separately to the model adjusted for all the above listed variables
bOnly patients treated with palliative chemotherapy were included in the analysis (N = 1274)